Shots:
- Thermo Fisher has entered into definitive agreement with Solventum to acquire its purification & filtration business for ~$4.1B in cash, adding value to its upstream and downstream biologics development & manufacturing
- Transaction is expected to close by the end of 2025, pending regulatory approval & customary closing conditions
- Solventum’s purification and filtration unit has team of 2,500 spread globally and generated ~$1B in 2024. Solventum’s P&F is complimentary to Thermofisher’s cell culture media and single use technologies for biologics development
Ref: BusinessWire | Image: Thermo Fisher Scientific & Solventum
Related News:- Carlyle to Acquire Baxter International’s Vantive Kidney Care Segment for $3.8B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
